[logo] HealthTree Foundation
more_vert
close
person Sign In / Create Account

Off-the Shelf CAR T Cell Therapy Targeting CS1 by Cellectis with David Siegel, MD, PhD, Hackensack University

Off-the Shelf CAR T Cell Therapy Targeting CS1 by Cellectis with David Siegel, MD, PhD, Hackensack University image

Off-the Shelf CAR T Cell Therapy Targeting CS1 by Cellectis with David Siegel, MD, PhD, Hackensack University


May 03, 2019 / 11:00AM MDT
HealthTree Podcast for Multiple Myeloma
link icon facebook logo X logo linkedin logo reddit logo email icon

Also listen to us on:

spotify apple podcast youtube

Episode Summary

David Siegel, MD, PhD
John Theurer Cancer Center / Hackensack University
Interview Date: May 3, 2019

CAR T cell therapy is making its way into the myeloma clinic. Most of of the early CAR T therapies have been personalized for each patient using a target of BCMA. In this new Phase I study, the CAR T treatment is an off-the-shelf treatment from a donor. The target for this Cellectis treatment is CS1. This study will open this year at several locations and will include patients who have relapsed most of the myeloma drugs, including another CS1 targeted therapy called elotuzumab. Learn more about this fascinating new approach to CAR T therapy from Dr. David Siegel, a leading myeloma researcher at Hackensack University. 

Thanks to our episode sponsor

Have Any Questions?

Thank you for your interest in the event. If you have any questions, we would love to help!

Feel free to give us a call or send us a message below.

support

Get In Touch With Us

phone

1-800-709-1113

email

Support@healthtree.org

More Podcast Episodes

All HealthTree resources available anywhere, anytime
Download our App
Download iOS App Download Android App
iphone app mockup
newsletter icon

Get the Latest Adult T-cell Leukemia / Lymphoma Updates, Delivered to You.

By subscribing to the HealthTree newsletter, you'll receive the latest research, treatment updates, and expert insights to help you navigate your health.